Activist investor filings with the SEC on Lindblad Expeditions Holdings, Kala Pharmaceuticals, Avid Technology, Xoma, CymaBay, and National Fuel Gas
Zacks.com featured highlights include: Kala Pharmaceuticals, Unicharm and Capcom
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the virtual BofA Securities 2020 Health Care Conference. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present a corporate overview on Wednesday, May 13th, 2020 at 4:20 p.m. ET.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, its product candidate for the short-term treatment of the signs and symptoms of dry eye disease. Kala believes this application will be considered a Class 2 resubmission, with a targeted six-month review timeline under the Prescription Drug User Fee Act (PDUFA). Kala is preparing for a potential U.S. approval and launch by the end of 2020.
Is (KALA) Outperforming Other Medical Stocks This Year?
Is (KALA) Outperforming Other Medical Stocks This Year?
Shares of Kala Pharmaceuticals (NASDAQ:KALA) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share increased 28.00% year over year to ($0.54), which missed the estimate of ($0.51).Revenue of $1,071,000 less by 22.73% year over year, which missed the estimate of $2,660,000.Guidance Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 07, 2020View more earnings on KALATime: 06:00 PM ETWebcast URL: https://edge.media-server.com/mmc/p/iivco2paRecent Stock Performance Company's 52-week high was at $11.7852-week low: $3.24Price action over last quarter: Up 74.47%Company Overview Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases.See more from Benzinga * Stocks That Hit 52-Week Highs On Monday * Stocks That Hit 52-Week Highs On Tuesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Kala Pharma (KALA) delivered earnings and revenue surprises of -5.88% and -57.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals
Kala Pharmaceuticals, Inc. ("Kala") (NASDAQ:KALA) today announced that the underwriters of its previously announced underwritten public offering of common stock, which closed on March 13, 2020, have exercised a portion of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. After giving effect to the sale of 979,371 additional shares of common stock in the option closing, the total number of shares of common stock sold by Kala in the offering increased to 16,979,371 shares, which resulted in aggregate gross proceeds of approximately $134.0 million to Kala, before deducting underwriting discounts and commissions and offering expenses.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies Virtual Healthcare Conference. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to participate in a fireside chat on Wednesday, June 3rd, 2020 at 8:30 a.m. ET.
As of late, it has definitely been a great time to be an investor in Kala Pharmaceuticals.
Top Ranked Momentum Stocks to Buy for May 26th
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the first quarter ended March 31, 2020.
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) resubmission for EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, its product candidate for the short-term treatment of the signs and symptoms of dry eye disease. The FDA stated that the NDA resubmission is a complete, Class 2 response to the Complete Response Letter (CRL) issued in August 2019, and the FDA set a Prescription Drug User Fee Act (PDUFA) goal date of October 30, 2020 for the completion of its review of the NDA.
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Joining me from the company are: Mark Iwicki, chairman, president, and chief executive officer; Todd Bazemore, chief operating officer; Mary Reumuth, chief financial officer; Kim Brazzell, chief medical officer; and Hongming Chen, chief scientific officer. Thank you, Niranjan.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).